A recent study from the lab focused on understanding the role of Neuropeptide Y in the regulation of anxiety will be the subject of an accompanying commentary in the journal Biological Psychiatry. The study provided new evidence that higher levels of NPY1 and NPY5 receptor expression in the central nucleus of the amygdala are associated with reduced anxiety-related behaviors early in life, setting the stage for future work aimed at developing novel anxiety-reducing compounds. This is particularly important because anxiety disorders are among the most common psychiatric disorders and existing treatment options are inconsistently effective or associated with significant adverse effects.

Or, check out the paper: